Physician profile
John E Carey
NPI 1821069055
$5,249.88
in general payments reported to CMS, 2019-2025
28 companies · $2,352 in 2025
The $2,352 reported for 2025 was more than what 81% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $225 · 2021: $245 · 2022: $508 · 2023: $1,002 · 2024: $572 · 2025: $2,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,491 · Travel and Lodging: $1,257 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.79 |
| Travel and Lodging | $1,256.64 |
| Education | $179.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,297.23 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Boston Scientific Corporation | $693.56 | 2020-2025 | Wavewriter Alpha Prime 16, Infinion 16, General - Pain Management |
| Abbott Laboratories | $642.40 | 2022-2024 | Proclaim, Eterna |
| Medtronic USA, INC. | $399.36 | 2019-2020 | |
| Abbvie INC. | $350.60 | 2023-2025 | Botox |
| Painteq LLC | $134.75 | 2023-2024 | Painteq |
| Relievant Medsystems, INC. | $133.39 | 2022 | |
| Pfizer INC. | $65.04 | 2023-2024 | |
| Depuy Synthes Sales INC. | $51.22 | 2020-2023 | Monovisc, Orthovisc |
| Vertos Medical, INC. | $40.22 | 2021 | |
| Si-Bone, INC. | $37.15 | 2025 | |
| Tersera Therapeutics LLC | $36.84 | 2019 | |
| Allergan, INC. | $34.94 | 2021 | |
| Curonix LLC | $31.63 | 2022-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.33 | 2024 | Relistor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $28.78 | 2023 | Aristada, Lybalvi |
| Arbor Pharmaceuticals, INC. | $28.02 | 2019 | |
| Stimwave Technologies Incorporated | $26.59 | 2019 | |
| Protega Pharmaceutials INC | $26.46 | 2023 | Roxybond |
| Scilex Pharmaceuticals INC. | $24.18 | 2023 | Ztlido |
| Biotronik Nro, INC. | $23.25 | 2025 | Prospera |
| Inogen, INC. | $21.84 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Amgen INC. | $19.34 | 2022 | |
| Lundbeck LLC | $17.75 | 2023 | Vyepti |
| Merz North America, INC. | $16.60 | 2019 | |
| Nevro Corp. | $14.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.69 | 2021 | |
| Eisai INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.